Expansion of the specialty pharmaceutical distribution network
First written in FY2018-Q1. 14 of 18 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Despite a challenging operating environment, including the negative impact of the mid-year drug price revision implemented in April 2025 and higher distribution costs, including personnel expenses, this segment reported net sales of ¥2,782,584 million, up 5.4% year on year, and operating income of ¥33,297 million, up 0.7%. The increase was driven by the revenue benefit of sales growth exceeding market growth, resulting from the promotion of the Neo-Primary strategy and increased handling of specialty pharmaceuticals and other products subject to restricted distribution.」
The company disclosed that promoting its Neo-Primary Strategy and increasing its handling of limited-distribution products had led to sales growth exceeding market growth, as well as higher revenue and profits. - FY2025-H1RestatedAnnual report
「In the wholesale business for prescription pharmaceuticals and other products, we are pursuing the key initiatives set out in the 22-24 medium-term management plan—“strengthening existing businesses,” “monetization through business transformation,” and “optimization, efficiency and standardization across the group”—in order to concentrate resources on specialty areas and medical products and transform the business through DX.」
The company continues its policy of prioritizing growth fields, including concentrating resources on specialty areas and medical products. - FY2024-Q1RestatedAnnual report
「In the wholesale business for prescription pharmaceuticals and other products, we are pursuing the key initiatives set out in the 22-24 medium-term management plan—“strengthening existing businesses,” “monetization through business transformation,” and “optimization, efficiency and standardization across the group”—in order to concentrate resources on specialty areas and medical products and transform the business through DX.」
The company continues its policy of prioritizing growth fields, including concentrating resources on specialty areas, under the 22-24 Medium-Term Management Plan. - FY2023-Q2RestatedAnnual report
「In addition, to concentrate resources on specialty fields and medical products and transform the business through DX, we are pursuing the key initiatives set forth in the 22-24 medium-term management plan: strengthening existing businesses, monetizing business transformation, and optimizing, improving efficiency and standardizing operations across the Group.」
The company continues its policy of prioritizing growth fields, including concentrating resources on specialty areas, as a key initiative under the 22-24 Medium-Term Management Plan. - FY2023-Q1RestatedAnnual report
「In the wholesale business for prescription pharmaceuticals and other products, we are pursuing the key initiatives set out in the 22-24 medium-term management plan—“strengthening existing businesses,” “monetization through business transformation,” and “optimization, efficiency and standardization across the group”—in order to concentrate resources on specialty areas and medical products and transform the business through DX.」
The company continues its existing policy of prioritizing growth fields, including a focus on specialty areas, as a key initiative under the new Medium-Term Management Plan. - FY2022-Q3RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company continued the key initiatives, including a focus on specialty products and centralized distribution, into the final year of the 19-21 Medium-Term Management Plan. - FY2022-Q1RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company continues to promote the key initiatives under the 19-21 Medium-Term Management Plan, including a focus on specialty products. - FY2021-Q3RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company continues to promote 3 key initiatives, including a focus on specialty products. - FY2021-Q2RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The focus on specialty products continues to be promoted as a key initiative under the 19-21 Medium-Term Management Plan. - FY2020-Q3RestatedAnnual report
「As part of its focus on specialty products, the consolidated subsidiary アルフレッサ株式会社 (head office: Chiyoda-ku, Tokyo; hereinafter, アルフレッサ) established the Specialty Business Promotion Department in October 2019 to build an organizational structure for promoting the specialty products business, and is actively developing an integrated distribution business together with the group company エス・エム・ディ株式会社 (head office: Chiyoda-ku, Tokyo).」
The establishment of the Specialty Business Promotion Department and centralized distribution with エス・エム・ディ continue to be described as key initiatives for specialty products, following the previous quarter. - FY2020-Q2AdvancedAnnual report
「As part of its focus on specialty products, the consolidated subsidiary アルフレッサ株式会社 (head office: Chiyoda-ku, Tokyo; hereinafter, アルフレッサ) established the Specialty Business Promotion Department in October of this year to build an organizational structure for promoting the specialty products business, and is actively developing an integrated distribution business together with the group company エス・エム・ディ株式会社 (head office: Chiyoda-ku, Tokyo).」
The Company established a Specialty Business Promotion Department to strengthen its operating structure for the specialty products business and moved to the stage of systematically promoting centralized distribution with エス・エム・ディ. - FY2020-Q1RestatedAnnual report
「As part of its focus on specialty products, the company is actively developing an integrated distribution business using its group company エス・エム・ディ株式会社 (head office: Chiyoda-ku, Tokyo).」
The Company continues to develop centralized distribution of specialty products using エス・エム・ディ as a key initiative under its new medium-term management plan. - FY2019RestatedAnnual report
「To expand specialty pharmaceutical sales and distribution, the Company actively developed centralized distribution using its group company エス・エム・ディ株式会社.」
The Company continues to promote the expansion of centralized distribution of specialty pharmaceuticals using エス・エム・ディ. - FY2019-Q3RestatedAnnual report
「To expand the sale and distribution of specialty pharmaceuticals, the company is actively developing an integrated distribution business using its group company エス・エム・ディ株式会社.」
The Company continues to promote the expansion of centralized distribution of specialty pharmaceuticals using エス・エム・ディ. - FY2019-Q2RestatedAnnual report
「To expand the sale and distribution of specialty pharmaceuticals, the company is actively developing an integrated distribution business using its group company エス・エム・ディ株式会社.」
The Company continues to expand centralized distribution of specialty pharmaceuticals using エス・エム・ディ. - FY2018-Q3RestatedAnnual report
「In the specialty pharmaceutical distribution business, a specialty pharmaceutical distribution network centered on エス・エム・ディ株式会社 (head office: Chiyoda-ku, Tokyo), which distributes orphan drugs, orphan medical devices and other products, and working with 富田薬品株式会社 (head office: Chuo-ku, Kumamoto City) and 株式会社モロオ (head office: Chuo-ku, Sapporo City), has begun handling new pharmaceuticals and is steadily expanding its track record.」
The Company continues to report the handling of new pharmaceuticals and expansion of results through the specialty pharmaceutical distribution network, but no new numerical milestone was disclosed. - FY2018-Q2AdvancedAnnual report
「As of the end of September 2017, the company had a track record of handling 7 products from 6 manufacturers. It will continue to strengthen its ability to serve patients, medical institutions and pharmaceutical manufacturers nationwide that require specialty pharmaceuticals.」
Specific results for the specialty pharmaceutical distribution network as of 30 September 2017 were disclosed: 6 manufacturers and 7 products handled. - FY2018-Q1First statedAnnual report
「In specialty pharmaceutical distribution, a growth area, the specialty pharmaceutical distribution network built in cooperation with 富田薬品株式会社, headquartered in Chuo Ward, Kumamoto City, and 株式会社モロオ, headquartered in Chuo Ward, Sapporo City, and originating with エス・エム・ディ株式会社, headquartered in Chiyoda Ward, Tokyo, which distributes orphan drugs, orphan medical devices and other products, is steadily expanding the number of products handled, including through the launch of distribution for new pharmaceuticals.」
Starting with エス・エム・ディ, the Company has built a distribution network for orphan drugs and medical devices in cooperation with 富田薬品 and モロオ. It has begun handling new pharmaceuticals and is increasing the number of products handled.